1163707-56-9 Usage
General Description
1-(4-bromopyridin-2-yl)cyclopropanecarbonitrile is a chemical compound with the molecular formula C9H7BrN. It is a nitrile derivative with a cyclopropane ring and a bromopyridine moiety. 1-(4-broMopyridin-2-yl)cyclopropanecarbonitrile has potential applications in medicinal chemistry and pharmaceutical research due to its structural features, which may impart unique biological activity. It is important for drug discovery and development, as well as in the study of chemical reactions and mechanisms. The synthesis and characterization of 1-(4-bromopyridin-2-yl)cyclopropanecarbonitrile may provide valuable insights into its properties and potential uses in various fields of science and technology.
Check Digit Verification of cas no
The CAS Registry Mumber 1163707-56-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,6,3,7,0 and 7 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1163707-56:
(9*1)+(8*1)+(7*6)+(6*3)+(5*7)+(4*0)+(3*7)+(2*5)+(1*6)=149
149 % 10 = 9
So 1163707-56-9 is a valid CAS Registry Number.
1163707-56-9Relevant articles and documents
HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
Paragraph 0176, (2020/10/21)
Heterocyclic compounds as Weel inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
ARYL-BIPYRIDINE AMINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS
-
Paragraph 0485, (2019/07/13)
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I): wherein A, X, Y, Z, Q, R1, R2, R3, R4, R5, and n are described herein.
THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
-
Page/Page column 154; 155, (2015/02/02)
Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
